Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2054275 | 0.84 | ENPP1 (0.41) | PARP1PDE10AENPP1SMN1; SMN2HCAR2 | |
| SCHEMBL6922600 | 0.82 | PARP1 (0.48) | PARP1PDE10APIM1PIM2TNKS2 | |
| SCHEMBL6922724 | 0.81 | PARP1 (0.48) | PARP1PDE10ATNKS2TNKSSMN1; SMN2 | |
| SCHEMBL6920370 | 0.77 | NPC1 (0.46) | PARP1PDE10ATNKS2SMN1; SMN2PARP14 | |
| SCHEMBL6921853 | 0.76 | CYP3A4 (0.45) | PDE10ATNKS2 | |
| SCHEMBL19116440 | 0.72 | KDM4C (0.59) | PARP1PDE10ATNKS2ENPP1SMN1; SMN2 | |
| SCHEMBL6921238 | 0.71 | PDE10A (0.49) | PARP1PDE10ATNKS2TNKSSMN1; SMN2 | |
| SCHEMBL12066523 | 0.70 | PDE10A (0.58) | PARP1PDE10ATNKS2TNKSSMN1; SMN2 | |
| SCHEMBL17298079 | 0.69 | TNKS2 (0.62) | PARP1PDE10ATNKS2ENPP1SMN1; SMN2 | |
| SCHEMBL12059535 | 0.69 | CYP3A4 (0.41) | TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | PARP1 3551/4885PDE10A 1514/4885PIM1 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.